Parabilis Medicines, Inc. (PBLS)
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Parabilis Medicines, Inc.
NASDAQ:PBLSHealthcare · Biotechnology
-9.21%$24.44
AH Close$24.79+1.43%vs close
AH Close$24.79+1.43%vs close
Mkt Cap$3.02B
Float101.16M
O/S123.53M
Inst Own80.1%
SI8.2%
Dilution
Delisting Issues Timeline
Financials Summary
Revenue$0
Net Income-$145.89M
Total Assets$80.82M
Free Cash Flow-$124.02M
Debt & Equity
Debt 11%
Preferred 92%
Total Debt$58.7M
Total Equity-$16.52M
Preferred Stock$509.97M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in PBLS's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$80.82M
Liabilities$97.34M
Accounts Receivable$0
Accounts Payable$17.27M
Inventory$0
PP&E (Net)$46.08M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 |
|---|---|---|
| Currency | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 |
| Revenue | $0 | $0 |
| YoY Growth | - | - |
| Cost of Revenue | $0 | $0 |
| Gross Profit | $0 | $0 |
| Gross Margin | - | - |
| Research and Development | $125.58M | $100.83M |
| Selling, General, and Administrative | $26.5M | $25.3M |
| Other | $0 | $0 |
| Total Operating Expenses | $152.08M | $126.13M |
| Operating Income (EBIT) | -$152.08M | -$126.13M |
| Operating Margin | - | - |
| Interest Expense | $1.52M | $1.49M |
| Interest Income | $3.39M | $6.41M |
| Other Income (Expense) | $6.19M | $8.21M |
| Income Before Tax (EBT) | -$145.89M | -$117.91M |
| Income Tax Expense | $0 | $0 |
| Net Income | -$145.89M | -$117.91M |
| Net Income Margin | - | - |
| Supplementary Data | ||
| EPS | -92.40 | -83.48 |
| Diluted EPS | -92.40 | -83.48 |
| Weighted Average OS | 2.02M | 1.93M |
| EBITDA | -$141.87M | -$114.33M |
| EBITDA Margin | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 |
|---|---|---|
| Currency | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 |
| Assets | ||
| Current Assets | ||
| Cash and Cash Equivalents | $27.71M | $47.28M |
| Short-Term Investments | $0 | $40.69M |
| Cash and Short-Term Investments | $27.71M | $87.98M |
| Accounts Receivable | $0 | $360K |
| Inventory | $0 | $0 |
| Other Current Assets | $1.65M | $3.87M |
| Total Current Assets | $29.36M | $92.21M |
| Long-Term Assets | ||
| Property, Plant & Equipment Net | $46.08M | $52.93M |
| Goodwill | $0 | $0 |
| Intangible Assets | $0 | $0 |
| Long-Term Investments | $0 | $0 |
| Deferred Tax Assets | $0 | $0 |
| Other Long-Term Assets | $5.39M | $4.12M |
| Total Long-Term Assets | $51.46M | $57.05M |
| Other Assets | $0 | $0 |
| Total Assets | $80.82M | $149.25M |
| Liabilities | ||
| Current Liabilities | ||
| Accounts Payable | $17.27M | $9.51M |
| Short-Term Debt | $13.08M | $2.5M |
| Current Income Tax Payable | $0 | $0 |
| Current Unearned Revenue | $0 | $0 |
| Other Current Liabilities | $10.3M | $6.97M |
| Total Current Liabilities | $56.79M | $32.41M |
| Long-Term Liabilities | ||
| Long-Term Debt | $0 | $12.79M |
| Long-Term Unearned Revenue | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 |
| Other Long-Term Liabilities | $2.74M | $3.58M |
| Total Long-Term Liabilities | $40.55M | $60.4M |
| Other Liabilities | $0 | $0 |
| Total Liabilities | $97.34M | $92.81M |
| Stockholders' Equity | ||
| Preferred Stock | $509.97M | $440.38M |
| Common Stock | $0 | $0 |
| Retained Earnings | -$541.5M | -$395.62M |
| Comprehensive Income & Other | $0 | $21K |
| Other Stockholders' Equity | $524.98M | $452.05M |
| Total Equity | -$16.52M | $56.44M |
| Minority Interest | $0 | $0 |
| Total Liabilities and Equity | $80.82M | $149.25M |
| Supplementary Data | ||
| Total Debt | $58.7M | $66.2M |
| Net Debt | $30.99M | $18.91M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 |
|---|---|---|
| Currency | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 |
| Operating Activities | ||
| Net Income | -$145.89M | -$117.91M |
| Depreciation & Amortization | $2.5M | $2.1M |
| Deferred Income Tax | $0 | $0 |
| Stock-Based Compensation | $3.32M | $4.31M |
| Changes in Working Capital: | ||
| Accounts Receivable | $360K | $106K |
| Inventory | $0 | $0 |
| Accounts Payable | $13.59M | $9.28M |
| Other Working Capital | -$4.83M | -$8.48M |
| Total Working Capital Change | $9.12M | $910K |
| Other Non-Cash Items | $7.24M | $6.98M |
| Net Cash from Operating | -$123.71M | -$103.61M |
| Investing Activities | ||
| Capital Expenditures | -$306K | -$879K |
| Acquisitions | $0 | $0 |
| Purchases of Investments | -$16.66M | -$90.86M |
| Sales of Investments | $56.73M | $121.98M |
| Other Investing Activities | $0 | $0 |
| Net Cash from Investing | $39.76M | $30.24M |
| Financing Activities | ||
| Debt Repaid | $3.08M | - |
| Common Stock Issuance | $67.46M | $78.08M |
| Common Stock Repurchases | $0 | $0 |
| Dividends Paid | $0 | $0 |
| Other Financing Activities | $0 | $0 |
| Net Cash from Financing | $64.38M | $78.08M |
| Forex Effect | $0 | $0 |
| Net Change in Cash | -$19.57M | $4.7M |
| Supplementary Data | ||
| Operating Cash Flow | -$123.71M | -$103.61M |
| Capital Expenditure | -$306K | -$879K |
| Free Cash Flow | -$124.02M | -$104.49M |
| Cash at Beginning | $50.14M | $45.44M |
| Cash at End | $30.57M | $50.14M |